Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Sector news Biotechnology & Medical Research - NEC
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- 2nd Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs -- Update
DJ
09/24GILEAD SCIENCES : to Slice List Prices of Liver Drugs
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/19AstraZeneca plots China robot offensive to counter price cuts
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans -- U..
DJ
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/12EUROPE : European stocks shrug off trade worries as oil stocks rally
RE
09/12Galapagos, Gilead bask in $4-6 billion new drug sales hope
RE
09/12GILEAD SCIENCES : Precision BioSciences Developing Hepatitis B Therapies
DJ
09/06Gilead, Galapagos Phase 2 Filgotinib Study Meets Primary Endpoint
DJ
09/05NOVARTIS : Immunotherapy Gathers Momentum With NHS Deal -- Update
DJ
09/05NOVARTIS : Kymriah to Be Used for Cancer Patients in the U.K.
DJ
09/04Factbox - Challenges facing German pharmaceutical company Bayer
RE
08/28GILEAD SCIENCES : UK Nixes Gilead Gene Therapy Citing Cost, Casting Doubt on Oth..
DJ
08/27Pfizer's Rare-Disease Drug Results Lifts Some Rivals -- Market Mover
DJ
08/22EXACT SCIENCES : Shares Jump 26%
DJ
08/22EXACT SCIENCES : Shares Surge on Co-Promotion Deal With Pfizer
DJ
08/22SIERRA ONCOLOGY : Acquires Momelotinib From Gilead Sciences
DJ
08/16REGENERON PHARMACEUTICALS : Teva Report Positive Phase 3 Fasinumab Results
DJ
08/03Roche Drug for Brain Disease Granted European Fast-Track
DJ
08/02Regeneron Closes Up 7% After 2Q Earnings Beat -- Data Talk
DJ
08/02REGENERON PHARMACEUTICALS : Beats Earnings Estimates
DJ
07/31UNITED THERAPEUTICS : Medtronic Get FDA OK for Remodulin Implantable System
DJ
07/27JOHNSON & JOHNSON : J&J's Janssen Gets Positive CHMP Opinion for Darzalex as Fro..
DJ
07/27Amgen profit beats Street view, will not raise prices again in 2018
RE
07/26Upbeat Roche bests rival Novartis as new drugs fuel growth
RE
07/26JOHN MILLIGAN : Gilead CEO Milligan To Leave -- WSJ
DJ
07/25GILEAD SCIENCES : CEO Stepping Down -- Update
DJ
07/24GSK's two-drug HIV treatment proves itself in key tests
RE
07/19Novartis, MorphoSys and Galapagos Shares Rise on News of Deal
DJ
07/11LIGAND PHARMACEUTICALS : Janssen Enter R&D Deal
DJ
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
05/25Pfizer to pay $23.85 million to settle U.S. co-payment kickback probe
RE
1  2  3  4  5  6  7  8  9  10Next
Financials (€)
Sales 2018 350 M
EBIT 2018 44,5 M
Net income 2018 33,9 M
Debt 2018 80,0 M
Yield 2018 -
P/E ratio 2018 75,73
P/E ratio 2019 57,24
EV / Sales 2018 7,89x
EV / Sales 2019 6,91x
Capitalization 2 682 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC AG34.63%3 150
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC31.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.81%14 156
SEATTLE GENETICS, INC.46.79%12 348
NEKTAR THERAPEUTICS1.93%10 176
ALNYLAM PHARMACEUTICALS, INC.-26.60%9 520
EXACT SCIENCES CORPORATION49.87%9 364
QIAGEN20.98%8 649
ICON PLC33.97%8 163
BIO-TECHNE CORP54.56%7 398
PRA HEALTH SCIENCES INC18.35%6 982
SAGE THERAPEUTICS INC-11.35%6 862
IONIS PHARMACEUTICALS INC0.42%6 746
ALKERMES PLC-22.95%6 455
GALAPAGOS NV (ADR)19.74%6 256
GALAPAGOS22.51%6 241
CHARLES RIVER LABORATORIES INTL. INC17.32%6 168
LIGAND PHARMACEUTICALS INC.95.97%5 484
UNITED THERAPEUTICS CORPORATION-15.30%5 347